Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03007303Unknown

The Relevance Between the microRNA-30e in Plasma and the Prognosis of Schizophrenia Patients

Role: lead

NCT04209166Not ApplicableUnknown

A Study of Individualized Diagnosis and Treatment for Major Depressive Disorder With Atypical Features

Role: collaborator

NCT02023567Not ApplicableUnknown

Objective Diagnostic Markers and Personalized Intervention in MDD Patients

Role: collaborator

All 3 trials loaded